

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:06:47 ON 07 MAY 2007

=> file ca

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CA' ENTERED AT 15:07:12 ON 07 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 May 2007 VOL 146 ISS 20

FILE LAST UPDATED: 3 May 2007 (20070503/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s azithromycin and (aspirin or acetylsalicylic)

3379 AZITHROMYCIN

20724 ASPIRIN

10115 ACETYLSALICYLIC

L1 91 AZITHROMYCIN AND (ASPIRIN OR ACETYLSALICYLIC)

=> s l1 and cholesterol

168700 CHOLESTEROL

L2 13 L1 AND CHOLESTEROL

=> d l2 1-13

L2 ANSWER 1 OF 13 CA COPYRIGHT 2007 ACS on STN

AN 146:309367 CA

TI Pharmaceutical compositions comprising ergot derivatives and ergolines for the treatment of carcinoid syndrome

IN Reiter, Rudolf; Tack, Johannes; Kalbe, Jochen; Horowski, Reinhard; Sigloch, Elisabeth; Palla, Heinz

PA Ergonex Pharma G.m.b.H., Switz.

SO Ger. Offen., 17pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------------|------|----------|----------------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | DE 102005041613 | A1 | 20070308 | DE 2005-102005041613 | 20050901 |
| PRAI | DE 2005-102005041613 | | 20050901 | | |
| OS | MARPAT 146:309367 | | | | |

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 13 CA COPYRIGHT 2007 ACS on STN
 AN 146:281100 CA
 TI Expandable medical devices with Parylene C und paclitaxel coating
 IN Sellin, Lothar; Han, Bock-Sun; Voss, Hans Dieter; Jilinski, Jakob
 PA Germany
 SO Ger. Offen., 10pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------------|------|----------|----------------------|----------|
| PI | DE 102005039126 | A1 | 20070222 | DE 2005-102005039126 | 20050818 |
| PRAI | DE 2005-102005039126 | | 20050818 | | |

L2 ANSWER 3 OF 13 CA COPYRIGHT 2007 ACS on STN
 AN 145:460599 CA
 TI Resorbable implants prepared from a metal base and polymer coating with drugs
 IN Orlowski, Michael
 PA Germany
 SO Ger. Offen., 12pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------------|------|----------|----------------------|----------|
| PI | DE 102005018356 | A1 | 20061026 | DE 2005-102005018356 | 20050420 |
| PRAI | DE 2005-102005018356 | | 20050420 | | |

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 13 CA COPYRIGHT 2007 ACS on STN
 AN 144:57599 CA
 TI Transdermal delivery system for statin combination therapy
 IN Lane, Edward M.
 PA Fairfield Clinical Trials, LLC, USA
 SO U.S. Pat. Appl. Publ., 7 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 2005281868 | A1 | 20051222 | US 2005-156744 | 20050621 |
| | WO 2006002127 | A1 | 20060105 | WO 2005-US21855 | 20050621 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRAI | US 2004-580734P | P | 20040621 | | |
| | US 2004-612828P | P | 20040927 | | |

L2 ANSWER 5 OF 13 CA COPYRIGHT 2007 ACS on STN
 AN 143:292623 CA
 TI Biocompatible coating, method, and use of medical surfaces
 IN Hoffmann, Erika
 PA Hemoteg G.m.b.H., Germany
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2005082434 | A2 | 20050909 | WO 2005-DE327 | 20050227 |
| | WO 2005082434 | A3 | 20051013 | | |
| | WO 2005082434 | B1 | 20051215 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2005216592 | A1 | 20050909 | AU 2005-216592 | 20050227 |
| | CA 2558141 | A1 | 20050909 | CA 2005-2558141 | 20050227 |
| | EP 1718347 | A2 | 20061108 | EP 2005-715031 | 20050227 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| | CN 1925881 | A | 20070307 | CN 2005-80006154 | 20050227 |
| | IN 2006MN01007 | A | 20070413 | IN 2006-MN1007 | 20060824 |
| PRAI | DE 2004-102004009850 | A | 20040228 | | |
| | US 2004-551761P | P | 20040311 | | |
| | WO 2005-DE327 | W | 20050227 | | |

L2 ANSWER 6 OF 13 CA COPYRIGHT 2007 ACS on STN
 AN 143:179636 CA
 TI Lipid-based dispersions for drug delivery
 IN Hu, Ning; Jensen, Gerard M.; Yang, Stephanie; Su-ming, Chiang
 PA Gilead Sciences, Inc., USA
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | WO 2005070465 | A2 | 20050804 | WO 2005-US1149 | 20050114 |
| | WO 2005070465 | A3 | 20060413 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2005206163 | A1 | 20050804 | AU 2005-206163 | 20050114 |
| | CA 2551807 | A1 | 20050804 | CA 2005-2551807 | 20050114 |

US 2005238705 A1 20051027 US 2005-35755 20050114
 EP 1706148 A2 20061004 EP 2005-705671 20050114
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
 BA, HR, IS, YU
 PRAI US 2004-536459P P 20040114
 WO 2005-US1149 W 20050114

L2 ANSWER 7 OF 13 CA COPYRIGHT 2007 ACS on STN
 AN 142:451759 CA
 TI Enteric capsule of liposome drug
 IN Chen, Tao; Wang, Jiucheng; Hu, Renle; Jiao, Yaqi
 PA Libang Medical Science and Technology Co., Ltd., Xi'an, Peop. Rep. China
 SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 17 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | CN 1483399 | A | 20040324 | CN 2002-139428 | 20020917 |
| PRAI | CN 2002-139428 | | 20020917 | | |

L2 ANSWER 8 OF 13 CA COPYRIGHT 2007 ACS on STN
 AN 142:397825 CA
 TI Biocompatible, biostable coating of medical surfaces composed of
 polysulfone and hydrophilic polymers
 IN Horres, Roland; Hoffmann, Michael; Faust, Volker; Hoffmann, Erika; Di
 Biase, Donato
 PA Hemoteg G.m.b.H., Germany
 SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|----------------------|----------|
| PI | WO 2005032611 | A2 | 20050414 | WO 2004-DE2184 | 20040929 |
| | WO 2005032611 | A3 | 20070322 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | DE 102004020856 | A1 | 20050414 | DE 2004-102004020856 | 20040428 |
| | AU 2004277302 | A1 | 20050414 | AU 2004-277302 | 20040929 |
| | CA 2540382 | A1 | 20050414 | CA 2004-2540382 | 20040929 |
| | EP 1667743 | A2 | 20060614 | EP 2004-786896 | 20040929 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| | BR 2004014849 | A | 20061121 | BR 2004-14849 | 20040929 |
| | JP 2007508039 | T | 20070405 | JP 2006-527276 | 20040929 |
| | US 2005129731 | A1 | 20050616 | US 2004-979977 | 20041103 |
| PRAI | DE 2003-10345132 | A | 20030929 | | |
| | US 2003-516295P | P | 20031103 | | |
| | DE 2004-102004020856 | A | 20040428 | | |
| | US 2004-571582P | P | 20040517 | | |
| | WO 2004-DE2184 | W | 20040929 | | |

L2 ANSWER 9 OF 13 CA COPYRIGHT 2007 ACS on STN
 AN 142:386006 CA
 TI Methods and means for modulating lipid metabolism
 IN Petyaev, Ivan
 PA Cambridge Theranostics Limited, UK
 SO PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2005034962 | A1 | 20050421 | WO 2004-GB4162 | 20040929 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2004280108 | A1 | 20050421 | AU 2004-280108 | 20040929 |
| | CA 2541815 | A1 | 20050421 | CA 2004-2541815 | 20040929 |
| | EP 1673098 | A1 | 20060628 | EP 2004-768705 | 20040929 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| | CN 1886142 | A | 20061227 | CN 2004-80035435 | 20040929 |
| | JP 2007507479 | T | 20070329 | JP 2006-530570 | 20040929 |
| | US 2007072814 | A1 | 20070329 | US 2006-574852 | 20061019 |
| PRAI | GB 2003-23348 | A | 20031006 | | |
| | WO 2004-GB4162 | W | 20040929 | | |

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 10 OF 13 CA COPYRIGHT 2007 ACS on STN
 AN 140:380661 CA
 TI Delivery composition and method
 IN Wright, D. Craig; Mauk, John E.
 PA USA
 SO U.S. Pat. Appl. Publ., 12 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | US 2004087564 | A1 | 20040506 | US 2002-284465 | 20021031 |
| | WO 2004041287 | A1 | 20040521 | WO 2003-US34699 | 20031031 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2003284387 | A1 | 20040607 | AU 2003-284387 | 20031031 |
| | EP 1565191 | A1 | 20050824 | EP 2003-776625 | 20031031 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 PRAI US 2002-284465 A 20021031
 WO 2003-US34699 W 20031031
 OS MARPAT 140:380661

L2 ANSWER 11 OF 13 CA COPYRIGHT 2007 ACS on STN
 AN 139:399770 CA
 TI Medical goods comprising heparin or chitosan-based hemocompatible coating
 IN Horres, Roland; Linssen, Marita Katharina; Hoffmann, Michael; Faust,
 Volker; Hoffmann, Erika; Di Biase, Donato
 PA Hemoteg G.m.b.H., Germany
 SO PCT Int. Appl., 93 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 2

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| PI WO 2003094990 | A1 | 20031120 | WO 2003-DE1253 | 20030415 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| DE 10221055 | A1 | 20031127 | DE 2002-10221055 | 20020510 |
| DE 10261986 | A1 | 20040318 | DE 2002-10261986 | 20020510 |
| AU 2003240391 | A1 | 20031111 | AU 2003-240391 | 20030415 |
| CA 2484269 | A1 | 20031120 | CA 2003-2484269 | 20030415 |
| CN 1543362 | A | 20041103 | CN 2003-800770 | 20030415 |
| EP 1501565 | A1 | 20050202 | EP 2003-729829 | 20030415 |
| EP 1501565 | B1 | 20061102 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003011446 | A | 20050315 | BR 2003-11446 | 20030415 |
| US 2005176678 | A1 | 20050811 | US 2003-513982 | 20030415 |
| CN 1665554 | A | 20050907 | CN 2003-815926 | 20030415 |
| JP 2005534724 | T | 20051117 | JP 2004-503070 | 20030415 |
| AT 344064 | T | 20061115 | AT 2003-729829 | 20030415 |
| IN 2004MN00606 | A | 20050218 | IN 2004-MN606 | 20041028 |
| ZA 2004008791 | A | 20050527 | ZA 2004-8791 | 20041028 |
| ZA 2004008757 | A | 20050531 | ZA 2004-8757 | 20041028 |
| PRAI US 2002-378676P | P | 20020509 | | |
| DE 2002-10221055 | A | 20020510 | | |
| WO 2003-DE1253 | W | 20030415 | | |

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 12 OF 13 CA COPYRIGHT 2007 ACS on STN
 AN 138:198641 CA
 TI Methods for the treatment of atherosclerosis
 IN Petyaev, Ivan
 PA Cambridge Theranostics Ltd., UK
 SO PCT Int. Appl., 115 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

| | | | | | |
|------|---|----|----------|----------------|----------|
| PI | WO 2003019198 | A2 | 20030306 | WO 2002-GB3863 | 20020822 |
| | WO 2003019198 | A3 | 20040304 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2002324128 | A1 | 20030310 | AU 2002-324128 | 20020822 |
| | GB 2380481 | A | 20030409 | GB 2002-19602 | 20020822 |
| | GB 2380481 | B | 20031203 | | |
| | GB 2381312 | A | 20030430 | GB 2002-19603 | 20020822 |
| | GB 2381312 | B | 20040218 | | |
| | GB 2381272 | A | 20030430 | GB 2002-19604 | 20020822 |
| | GB 2381272 | B | 20031203 | | |
| | US 2003166029 | A1 | 20030904 | US 2002-225437 | 20020822 |
| | US 2003190315 | A1 | 20031009 | US 2002-225460 | 20020822 |
| | US 2003194746 | A1 | 20031016 | US 2002-225461 | 20020822 |
| | US 7148028 | B2 | 20061212 | | |
| | EP 1456670 | A2 | 20040915 | EP 2002-758547 | 20020822 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| PRAI | GB 2001-20428 | A | 20010822 | | |
| | US 2001-323127P | P | 20010918 | | |
| | GB 2002-2774 | A | 20020206 | | |
| | US 2002-355655P | P | 20020206 | | |
| | GB 2002-4611 | A | 20020227 | | |
| | GB 2002-16530 | A | 20020716 | | |
| | GB 2002-16755 | A | 20020718 | | |
| | GB 2002-774 | A | 20020602 | | |
| | WO 2002-GB3863 | W | 20020822 | | |

L2 ANSWER 13 OF 13 CA COPYRIGHT 2007 ACS on STN

AN 134:362292 CA

TI Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

IN Farr, Spencer

PA Phase-1 Molecular Toxicology, USA

SO PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001032928 | A2 | 20010510 | WO 2000-US30474 | 20001103 |
| | WO 2001032928 | A3 | 20020725 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | US 1999-165398P | P | 19991105 | | |
| | US 2000-196571P | P | 20000411 | | |

=> d 12 1-13 an ab

L2 ANSWER 1 OF 13 CA COPYRIGHT 2007 ACS on STN

AN 146:309367 CA

AB The invention discloses the use of ergot derivs. and/or ergolines for the prophylaxis and treatment of gastrointestinal and endocardial diseases which are caused by neuroendocrine malfunction of different etiol., in particular arising from carcinoid tumors, irritable intestine, or autoimmune diseases.

L2 ANSWER 2 OF 13 CA COPYRIGHT 2007 ACS on STN

AN 146:281100 CA

AB The invention concerns an expandable medical good, e.g. blood vessel-diluting balloon catheters that are coated with Parylene C and/or with aloe extract and paclitaxel. Addnl. drugs and other substances can be included in the coating layer. Thus a chromium-cobalt PTCA stent was spray-coated with a methanolic solution of Aloe Vera extract and paclitaxel.

L2 ANSWER 3 OF 13 CA COPYRIGHT 2007 ACS on STN

AN 145:460599 CA

AB The invention concerns resorbable implants that are prepared from metals, or metal alloys and coated with biodegradable polymers that include active substances, e.g. anticancer drugs, antiinflammatory agents, antiphlogistics, cytotoxic, antithrombotic agents, corticoids, sex hormones, statins, epothilone, prostacyclins, or angiogenesis inductors. Stents for blood vessels, urinary tract, respiratory tract, bile duct, and gastrointestinal tract can be prepared. Thus a stent was prepared from (weight/weight): zinc 90; magnesium 6; calcium 1; yttrium 2; other metals, salts, nonmetals, carbon, sulfur, oxygen, nitrogen, and(or) hydrogen 1. The stent was dip-coated with a solution of a polyglycol with doxorubicin.

L2 ANSWER 4 OF 13 CA COPYRIGHT 2007 ACS on STN

AN 144:57599 CA

AB The present invention relates to transdermal drug delivery systems for treatment of lipid disorders and the safer delivery of statin drugs to provide lessened danger or severity of side effects. The transdermal composition comprises (a) a statin drug, and (b) a drug contraindicated for concomitant administration with said statin drug, such as a non-statin cholesterol- and/or lipid-lowering drug, an antihypertensive drug, an α - or β -blocker, an angiotensin receptor blocker, an antihyperglycemic agent, an ACE inhibitor, a cardiovascular drug, etc.

L2 ANSWER 5 OF 13 CA COPYRIGHT 2007 ACS on STN

AN 143:292623 CA

AB The invention relates to medical products having a surface that is at least partially covered by a polymer layer. Said polymer layer is preferably formed by autopolymerization. Substances containing at least one multiple bond, especially unsaturated fatty acids comprising an alkyl chain consisting of preferably between 7 and 50 carbon atoms are polymerized. Other substances which do not participate in the polymerization can be added to the substances participating in the polymerization reaction. Said substances are preferably saturated fatty acids and fatty acid derivs. The invention also relates to methods for producing such medical products, and to the use of the same. Thus a non-expanding stent prepared from LVM 316 stainless steel was spray-coated with a mixture of linseed oil and paclitaxel at a ratio of 80:20 in chloroform at a ratio of 1:1. Thereafter chloroform was evaporated and stored at 80°C.

L2 ANSWER 6 OF 13 CA COPYRIGHT 2007 ACS on STN

AN 143:179636 CA

AB The invention provides lipid-based dispersion comprising comprising, phosphatidylcholine, an anionic phospholipid, up to 1% cholesterol by weight of total lipids, and a therapeutic agent, wherein the mean particle

size measured by dynamic light scattering is <100 nm. The invention also provides pharmaceutical compns. comprising such a dispersion as well as methods of producing a therapeutic effect in a mammal comprising administering an effective amount of such a dispersion. Soy-phosphatidylcholine, DSPG, and propofol were dissolved in a 1:1 mixture of methanol and chloroform at a molar ratio of Soy-PC:DSPG of 1:0.4 and a weight ratio of (Soy-PC + DSPG):propofol of 10:1. Solvents were removed by evaporation and the films were then hydrated in 9% sucrose at desired drug concns. and sonicated to form liposomes.

L2 ANSWER 7 OF 13 CA COPYRIGHT 2007 ACS on STN

AN 142:451759 CA

AB The enteric capsule is composed of drug 0.01-80.0, phospholipid 5.0-75.0, cholesterol 0.1-5.0, vitamin E 0-5.0, protectant 5.0-80.0, diluter 1.0-70.0, flow aid 0.01-10.0%, and enteric capsule. The drug is bezafibrate, cyclosporin, methotrexate, fluorouracil, mitomycin, cortisone, hydrocortisone, prednisone, methyltestosterone, danazol, norethisterone, megestrol acetate, insulin, tolbutamide, glibornuride, glipizide, glicaramide, vitamin A, vitamin D, vitamin B2, vitamin E, erythromycin, erythromycin ethylsuccinate, midecamycin, acetylspiramycin, roxithromycin, clarithromycin, azithromycin, rokitamycin, sulfadiazine, sulfadiazine Ag, sulfamethoxazole, furazolidone, indomethacin, aspirin, ibuprofen, etc. The protectant is mannitol, lactose, NaCl, glucose, gelatin hydrolyzate, etc. The diluter is starch, dextrin, sugar, lactose, glucose, mannitol, microcryst. cellulose, CaSO₄, CaCO₃, MgO, Al(OH)₃, polyvinylpyrrolidone, hydroxypropyl cellulose, alginate, etc. The flow aid is SiO₂ micropowder, talc, stearic ester, Ca stearate, Mg stearate, hydrogenated plant oil, polyethylene glycol, Na dodecyl sulfate, etc.

L2 ANSWER 8 OF 13 CA COPYRIGHT 2007 ACS on STN

AN 142:397825 CA

AB The invention relates to medical products comprising at least one biocompatible biostable polysulfone coating. Said polysulfone coating makes it possible, via the admixt. of an adequate quantity of at least one hydrophilic polymer, to control the elution kinetics of the at least one antiproliferative, anti-inflammatory, antiphlogistic, and/or antithrombogenic agent that is introduced and/or applied while allowing different agents or agent concns. to be spatially separated with the aid of the layer system of biostable polymers. Also disclosed are a method for producing said medical products and the use thereof particularly in the form of stents for preventing restenosis. Thus a 2 g base-coat solution for spray coating contained 17.6 mg polyethersulfone (Udel form Solvay) in chloroform. The 3 g chloroformic topcoat solution included 25.2 g polyethersulfone and 1,2 mg PVP.

L2 ANSWER 9 OF 13 CA COPYRIGHT 2007 ACS on STN

AN 142:386006 CA

AB The invention relates to modulation of lipid metabolism, in particular redns. in the levels of total cholesterol and apolipoprotein, of an individual. This modulation is achieved by combined administration of both anti-microbial and metal-chelator compds. Various therapeutic applications of this lipid modulation are provided.

L2 ANSWER 10 OF 13 CA COPYRIGHT 2007 ACS on STN

AN 140:380661 CA

AB A composition which includes a membrane modulators is disclosed. The composition

can be used in a wide range of therapies for delivering a membrane modulator which play an active function in regulating, controlling or causing a desired therapeutic effect to a target cell. For example, a progesterone-containing composition was prepared by mixing glycerol monostearate, progesterone, polyoxyethylene (20) sorbitan monostearate, and

cetylpyridinium chloride (4.1:2.22:1:1.57) as a hydrophobic phase with water as a hydrophilic phase. The final non-Newtonian fluid product was 60% water and the final concentration of the progesterone was approx. 100 mg/g.

L2 ANSWER 11 OF 13 CA COPYRIGHT 2007 ACS on STN
AN 139:399770 CA

AB The invention relates to oligo- and polysaccharides containing the sugar structural element N-acylglucosamine or N-acylgalactosamine, in addition to the use thereof for producing hemocompatible surfaces and to methods for coating surfaces in a hemocompatible manner with said oligo- and polysaccharides, which constitute the common biosynthetic precursor substances of heparin, heparan sulfates and chitosan. The invention also relates to methods for producing the oligo- and/or polysaccharides, in addition to diverse application options involving hemocompatible surfaces. The invention specifically relates to the use of the oligo- and/or polysaccharides on stents involving at least one hemocompatible coating that has been applied according to the invention and that contains an anti-proliferative, anti-inflammatory and/or athrombogenic active ingredient, to methods for producing said stents and to the use of the latter for preventing restenosis. Thus desulfated and reacylated heparin was prepared; the Ac-heparin product was used for coating coronary metal stents. The stents were implanted in swines; after four weeks the animals were anesthetized and the artery segments removed for histomorphometric anal.

L2 ANSWER 12 OF 13 CA COPYRIGHT 2007 ACS on STN
AN 138:198641 CA

AB Methods are disclosed for the treatment of atherosclerosis. The invention relates to the identification of lipid oxidizing antibodies as a key pathogenic factor in atherosclerotic disorders. These disorders may be treated by inhibiting this antibody mediated lipid oxidation and methods and means for identifying and producing inhibitory agents are provided.

L2 ANSWER 13 OF 13 CA COPYRIGHT 2007 ACS on STN
AN 134:362292 CA

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.